Skip to Main content Skip to Navigation
Journal articles

18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Cote d'Ivoire: a cohort study.

Abstract : ABSTRACT: OBJECTIVE: To assess the 18-month field effectiveness on severe events of a pediatric package combining early HIV-diagnosis and targeted cotrimoxazole prophylaxis in HIV-infected children from age six-week before the antiretroviral era, in Abidjan, Cote d'Ivoire. METHODS: Data from two consecutive prevention of HIV mother-to-child transmission programs were compared: the ANRS 1201/1202 Ditrame-Plus cohort (2001-2005) and the pooled data of the ANRS 049a Ditrame randomized trial and its following open-labeled cohort (1995-2000), used as a reference group. HIV-infected pregnant women [greater than or equal to]32-36 weeks of gestation were offered a short-course peri-partum antiretroviral prophylaxis (ZDV in Ditrame, and ZDV+/-3TC+single-dose (sd) NVP in Ditrame-Plus). Neonatal prophylaxis was provided in Ditrame-Plus only: 7-day ZDV and sdNVP 48-72h after birth. A 6-week pediatric HIV-RNA diagnosis was provided online in the Ditrame-Plus while it was only oriented on clinical symptoms in Ditrame. Six-week HIV-infected children received a daily cotrimoxazole prophylaxis in Ditrame-Plus while no prophylaxis was provided in Ditrame. The determinants of severe events (death or hospitalization) were assessed in a Cox regression model. RESULTS: Between 1995 and 2003, 98 out of the 1121 live-births were diagnosed as HIV-infected in peri-partum: 45 from Ditrame-Plus and 53 from Ditrame. The 18-month Kaplan-Meier cumulative probability of presenting a severe event was 66% in Ditrame-Plus (95% confidence interval [95%CI]: 50%-81%) and 77% in Ditrame (95%CI: 65%-89%), Log Rank test: p=0.47. After adjustment on maternal WHO clinical stage, maternal death, 6-week pediatric viral load, birth-weight, and breastfeeding exposure, the 18-month risk of severe event tended to be lower in Ditrame-Plus than in Ditrame but this trend was not statistically significant (adjusted Hazard Ratio (aHR): 0.55, 95%CI: 0.3-1.1; p=0.07). Maternal death was the only variable determinant of the occurrence of severe events in children (aHR: 3.73; CI: 2.2-11.2; p=0.01). CONCLUSION: We probably lacked of statistical power to show a significant major effect of early cotrimoxazole in HIV-infected infants. However, these results argued that an early pediatric HIV-diagnosis could better target infant eligible for HIV-care and reduce the family burden of HIV-infection in the context of universal antiretroviral access.
Document type :
Journal articles
Complete list of metadatas

Cited literature [31 references]  Display  Hide  Download
Contributor : Evelyne Mouillet <>
Submitted on : Wednesday, May 21, 2008 - 9:45:52 AM
Last modification on : Friday, October 23, 2020 - 4:44:37 PM
Long-term archiving on: : Friday, May 28, 2010 - 7:45:10 PM




Jérôme Harambat, Patricia Fassinou, Renaud Becquet, Pety Touré, François Rouet, et al.. 18-month occurrence of severe events among early diagnosed HIV-infected children before antiretroviral therapy in Abidjan, Cote d'Ivoire: a cohort study.. BMC Public Health, BioMed Central, 2008, 8 (1), pp.169. ⟨10.1186/1471-2458-8-169⟩. ⟨inserm-00281165⟩



Record views


Files downloads